This animation explains research by Schaeffer Center experts that offers one of the most comprehensive looks at the insulin distribution chain and shows which players are profiting, and by how much, from selling insulin. The video breaks down the players in the distribution chain as well as how the share of profits from insulin changed between 2014 and 2018.Read Full Story
Featured White Papers
Some claim that FDA approval of drugs with uncertain efficacy today will slow future innovation. In fact, the relationship is much more complex.
Minimally invasive technologies are capacity-conserving technologies that could reduce burdens on healthcare providers and hospitals while also shielding patients from unnecessary in-hospital exposure to pathogens.
Health technology assessment (HTA) can help achieve the dual health policy goals of ensuring affordability and encouraging innovation.
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.